David Luckenbaugh
Statistician / researcher at the National Institute of Mental Health (NIMH), NIH
Data updated
Papers
Trials
Research Footprint
David Luckenbaugh appears in 9 tracked papers (2010–2018), most studied alongside Ketamine and Placebo, across Depressive Disorders, Bipolar Disorder and Major Depressive Disorder (MDD).
Most-cited paper: A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression (967 citations).
Frequent co-authors: Carlos Zarate, Nancy Elizabeth Brutsche and Mark John Niciu.
Background & Research
David A. Luckenbaugh is a researcher/statistician associated with the National Institute of Mental Health at the NIH. His publications span depression, bipolar disorder, suicidality, sleep biomarkers, and ketamine-related clinical trials, often in collaboration with Carlos A. Zarate Jr. and colleagues at NIMH. He is listed on multiple influential papers examining the rapid antidepressant and anti-suicidal effects of ketamine.
Key Impact
He has been a key quantitative collaborator on foundational ketamine and rapid-acting antidepressant studies in treatment-resistant depression and bipolar depression.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations David Luckenbaugh is associated with.